Related posts

Tech and oil decline3 Popular Stocks of the Year, Part 1Wall Street advances, Bay Street pauses
Investor Insights

This summary was created by AI, based on 1 opinions in the last 12 months.

BioNTech (BNTX-Q) has recently been recognized as a top pick by analysts, highlighting its positive trajectory and promising performance. The stock has achieved a notable increase of 9.3%, indicating strong market confidence and investor interest. The recommendation to adjust the stop-loss from $78 to $95 signifies a proactive approach to risk management while maintaining a bullish outlook. Given its advancements and expert endorsements, BioNTech appears to be well-positioned for continued growth in the biotechnology sector. Overall, the combination of solid past performance and expert support suggests that BioNTech could be a valuable addition to a well-rounded investment portfolio.

Consensus
Positive
Valuation
Fair Value
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Dec 21/23, Up 9.3%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with BNTX is progressing well.  To remain disciplined, we recommend trailing up the stop (from $78) to $95 at this time.  

premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly

This $24 billion German based pharma company has received approvals to continue advancement into a new uterine cancer treatment.  It trades at 8x trailing earnings, 1.1x book and supports a 23% ROE.  Cash reserves are growing, while stock is bought back.  We recommend placing a stop-loss at $78, looking to achieve $137 -- upside potential of 31%.  Yield 0%  

(Analysts’ price target is $137.07)
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Sep 14/23, Down 13.2%)Stockchase Research Editor: Michael O’Reilly

Our PAST TOP PICK with ALC has triggered its stop at $14.50. To remain disciplined, we recommend covering the position at this time. 

premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly

The $28 billion biotech just received FDA approval of their updated COVID vaccine.  It trades at 6x earnings, 1.3x book and supports a 23% ROE.  We like that cash reserves are growing, while shares are bought back and debt is retired.   We recommend placing a stop-loss at $100, looking to achieve $161 -- upside potential of 40%.  Yield 0% 

(Analysts’ price target is $161.34)
PAST TOP PICK
(A Top Pick May 14/21, Down 28%) Has kept shares in company and likes the business model. Cash from vaccine sales will be used to make other vaccines and therapeutics. Long term is a good investment. Lots of R & D opportunities.
BUY
He likes it. He hopes China's government buys their Covid vaccine.
TOP PICK

Provides the key insight into mRNA that underlies the Covid vaccine. The mRNA technology can be developed into therapies that are targeted and safe. They are working on a flu vaccine as well as a cancer vaccine. Their pipeline is vast and the coronavirus vaccine is giving a huge cash hoard to pay for R&D. (Analysts’ price target is $185.00)

Showing 1 to 7 of 7 entries
  • «
  • 1
  • »

BioNTech(BNTX-Q) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 1

Stockchase rating for BioNTech is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

BioNTech(BNTX-Q) Frequently Asked Questions

What is BioNTech stock symbol?

BioNTech is a American stock, trading under the symbol BNTX-Q on the NASDAQ (BNTX). It is usually referred to as NASDAQ:BNTX or BNTX-Q

Is BioNTech a buy or a sell?

In the last year, 1 stock analyst published opinions about BNTX-Q. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for BioNTech.

Is BioNTech a good investment or a top pick?

BioNTech was recommended as a Top Pick by on . Read the latest stock experts ratings for BioNTech.

Why is BioNTech stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is BioNTech worth watching?

1 stock analyst on Stockchase covered BioNTech In the last year. It is a trending stock that is worth watching.

What is BioNTech stock price?

On 2025-03-14, BioNTech (BNTX-Q) stock closed at a price of $98.84.